Resources
20 Results (showing 1 - 10)
Results sorted by posted date (oldest first)
Results sorted by posted date (oldest first)
Posted 11/19/2019 (updated 3/28/2024)
Posted 3/19/2020 (updated 3/28/2024)
To help local leaders respond to this epidemic, USDA has worked to build infrastructure for prevention, treatment and recovery, facilitate partnerships, and drive innovation in rural communities.
Posted 4/3/2020 (updated 3/28/2024)
This RSV Breakout Session was held in the Monument Room on Wednesday, March 4, 2020, at 4:15 PM
Posted 8/11/2020 (updated 4/2/2024)
Non-fatal opioid overdose (NFOO) is a significant cause of opioid-related morbidity in the United States. As the number of NFOOs continues to grow, it is important to understand the short- and long-term consequences of NFOO. This report examines the existing literature on the acute and chronic health and functional outcomes of individuals who experience NFOO, and also identifies differences in outcomes for NFOOs involving illicitly-manufactured fentanyl.
Posted 9/22/2020 (updated 3/29/2024)
The Post-Overdose Response (PORT) Toolkit was developed as a resource for North Carolina communities who are interested in creating a post-overdose response team (PORT) in their jurisdiction.
Posted 10/13/2020 (updated 3/27/2024)
The CDC’s National Vital Statistics System has been updated to now include data related to February 2020 overdose mortality, with trends indicating further worsening of the nation’s opioid epidemic.
Posted 5/26/2021 (updated 4/10/2024)
Opioid dependence is a chronic relapsing disorder with considerable individual and global public health burden. The current standard of care for opioid dependence includes treatment with methadone or sublingual (SL) buprenorphine or buprenorphine-naloxone (hereafter, buprenorphine), combined with psychosocial and behavioral support. Both medications are associated with reductions in mortality, illicit opioid use, bloodborne viral infections, and criminal behavior as well as better cost-effectiveness than no treatment or psychosocial treatment alone. Buprenorphine is a partial μ-opioid receptor agonist, enabling office-based treatment for nonsupervised or take-home use of the medication. However, SL formulations of buprenorphine are prone to nonmedical use (eg, injecting, diversion), prompting models of care, particularly in the early phases of treatment, requiring regular attendance at clinics or pharmacies for administration of doses.
Posted 8/4/2021 (updated 4/2/2024)
This program brief highlights the Alliance for Prevention and Wellness (APW) use of Overdose Detection Mapping Application Program (ODMAP) data to target a broad range of substance use prevention and education activities to ZIP codes with the highest rate of overdoses. Source: Bureau of Justice Assistance (BJA)-Supported Comprehensive Opioid, Stimulant, and Substance Abuse Program (COSSAP).
Posted 9/15/2021 (updated 4/2/2024)
Background: Opioid overdose has become the leading cause of death among adults between 25 and 54 years old in the U.S. The purpose of this study is to explore the social and relational factors that shape the current opioid overdose epidemic.
Posted 9/15/2021 (updated 4/2/2024)
Background: Rates of fatal overdose (OD) from synthetic opioids rose nearly 60 % from 2016 to 2018. 911 Good Samaritan Laws (GSLs) are an evidenced-based strategy for preventing OD fatality. This study describes patrol officers’ knowledge of their state’s GSL, experience with OD response, and their perspectives on strategies to prevent and respond to opioid OD.